Method of providing sustained analgesia with buprenorphine
AssigneeEuro-Celtique S.A.
InventorsRobert Reder, Paul Goldenheim, Robert Kaiko
Life of this patent
Estimating the term…
Abstract
A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
Claims8
-67. (canceled)
A method of treating pain in humans, comprising administering buprenorphine to human patients by applying a transdermal delivery system to the skin of said patient, and maintaining said transdermal delivery system in contact with said patient's skin for 168 hours;
- wherein said transdermal delivery system comprises an adhesive matrix layer comprising 10% buprenorphine, 10 to 15% levulinic acid, about 10% oleyoleate, 55 to 70% polyacrylate and 0 to 10% polyvinylpyrrolidone.
A method of treating pain in humans, comprising administering buprenorphine to human patients by applying a transdermal delivery system to the skin of said patient, and maintaining said transdermal delivery system in contact with said patient's skin for 168 hours;
- wherein said transdermal delivery system comprises an adhesive matrix layer comprising 10% buprenorphine, 10 to 15% levulinic acid, about 10% oleyoleate, 55 to 70% polyacrylate and 0 to 10% polyvinylpyrrollidone;
- and
- wherein the transdermal delivery system provides a nominal delivery rate of 12.5 μg/hr to 100 μg/hr;
- and the total amount of buprenorphine contained in the transdermal delivery system is about 5 mg to about 40 mg.
Dependencies are inferred from the claim text.